PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 96 filers reported holding PHATHOM PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $59,000 | +63.9% | 5,716 | +128.5% | 0.00% | – |
| Q2 2023 | $36,000 | +176.9% | 2,502 | +32.7% | 0.00% | – |
| Q1 2023 | $13,000 | -71.7% | 1,885 | -54.5% | 0.00% | – |
| Q4 2022 | $46,000 | +1433.3% | 4,139 | +1378.2% | 0.00% | – |
| Q3 2022 | $3,000 | +200.0% | 280 | +115.4% | 0.00% | – |
| Q2 2022 | $1,000 | -94.1% | 130 | -89.5% | 0.00% | – |
| Q1 2022 | $17,000 | -80.5% | 1,244 | -72.0% | 0.00% | – |
| Q4 2021 | $87,000 | +45.0% | 4,447 | +138.1% | 0.00% | – |
| Q3 2021 | $60,000 | +27.7% | 1,868 | +34.7% | 0.00% | – |
| Q2 2021 | $47,000 | +88.0% | 1,387 | +109.5% | 0.00% | – |
| Q1 2021 | $25,000 | – | 662 | +9357.1% | 0.00% | – |
| Q3 2020 | $0 | -100.0% | 7 | -65.0% | 0.00% | – |
| Q2 2020 | $1,000 | -92.3% | 20 | -96.1% | 0.00% | – |
| Q1 2020 | $13,000 | -40.9% | 514 | -25.8% | 0.00% | – |
| Q4 2019 | $22,000 | – | 693 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 2,484,274 | $27,873,554 | 11.71% |
| Frazier Life Sciences Management, L.P. | 8,407,152 | $94,328,245 | 5.86% |
| Abingworth LLP | 1,435,106 | $16,101,889 | 5.25% |
| Opaleye Management Inc. | 417,500 | $4,684,350 | 1.63% |
| 683 Capital Management, LLC | 1,350,000 | $15,147,000 | 1.28% |
| Newtyn Management, LLC | 484,074 | $5,431,310 | 1.12% |
| Penn Mutual Asset Management | 62,802 | $704,638 | 0.79% |
| StepStone Group LP | 422,085 | $4,735,794 | 0.62% |
| MPM BioImpact LLC | 195,942 | $2,198,469 | 0.57% |
| Avidity Partners Management LP | 1,900,000 | $21,318,000 | 0.46% |